Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지

표면활성제와 저용량 methylprednisolone으로 치료하였던 급성 호흡 곤란 증후군 1례

A case of acute respiratory distress syndrome treated with surfactant and low dose methylprednisolone

  • 최보연 (가톨릭대학교 의과대학 소아과학교실) ;
  • 김경모 (가톨릭대학교 의과대학 소아과학교실) ;
  • 윤종서 (가톨릭대학교 의과대학 소아과학교실) ;
  • 이준성 (가톨릭대학교 의과대학 소아과학교실)
  • Choi, Bo Yeon (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Kim, Kyong Mo (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Yoon, Jong Seo (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Lee, Joon Sung (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • 투고 : 2005.09.29
  • 심사 : 2005.12.09
  • 발행 : 2006.04.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

급성 호흡곤란 증후군은 다양하게 유발되는 신체의 손상에 대한 방어기전으로 염증반응이 유발되어 생성되는 폐포 내의 부종으로 인해 호흡곤란과 저산소증이 초래되는 질환이다. 이 질환에서 표면활성제의 결핍과 폐포 표면 장력의 증가로 인해 폐포 동원에 장애가 오는 것이 결정적인 병인이고 표면활성제의 보충이 저산소증을 개선시킴으로써 중요한 치료 방안이 될 수 있다는 가설이 제시되었고 실제로 소아 환자들에서 저산소증을 개선시키고 증상의 호전을 얻었던 보고들이 여러 차례 있었다. 또한 이 질환의 주요 병인인 폐에서의 염증 반응에 주안점을 두고 스테로이드를 투여해 본 연구들에서 저용량 methylprednisolone으로 증상이 호전되고 생존율이 향상되었다는 결론을 얻은 바 있으나 두 치료 모두 ARDS에서 일반적인 적용은 확립되어 있지 않은 실정이다. 저자들은 급성 호흡곤란 증후군으로 진단받은 61일된 소아가 인공 호흡기 등의 보존적인 치료에 반응하지 않고 지속적으로 증상의 악화를 보이다가 표면활성제 120 mg/kg를 기도 내로 주입한 후 호흡곤란 증상과 저산소증 호전되고 $PaO_2/FiO_2$ 상승, 이후 저용량 methylprednisolone을 투여(2 mg/kg 14일간, 1 mg/kg 7일간, 0.5 mg/kg 7일간, 0.25 mg/kg 2일간, 0.125 mg/kg/d 2일간)한 후 2개월간의 추적 관찰에서 증상의 재발없고 방사선학적 검사상 섬유화 등의 합병증을 보이지 않았던 1례를 보고하는 바이다.

The major pathogenesis of acute respiratory distress syndrome (ARDS) is an inflammatory process that results from a diversity of injuries to the body. Due to the various cytokines and vasoactive peptides released from the endothelium, the vascular permeability is increased; the migration of inflammatory cells and the leakage of plasma proteins then occur and edema develops in the alveolus. There is a hypothesis that the impairment of alveolar recruitment in ARDS is caused by a defect of the surfactant system and the resultant increase of alveolar surface tension. This has been studied in pediatric patients in ARDS; after the administration of surfactant, hypoxia, respiratory symptoms and survival chances were improved. To alleviate the major pathogenic mechanism in this disease, that is to say, inflammation of the lung, steroids have been used and studied as another treatment modality for ARDS, and it has been concluded that the administration of low dose methylprednisolone may improve patients' symptoms and survival rates. We report here on a case of a young infant admitted with ARDS, who, after the intratracheal administration of 120 mg/kg surfactant, on $PaO_2/FiO_2$ was elevated. Subsequent low doses of methylprednisolone were given, and the symptoms did not recur, and no fibrotic change was shown during the follow-up period of 2 months.

키워드

참고문헌

  1. Zilberberg MD, Epstein SK. Acute lung injury in the medical ICU : co-morbid conditions, age, etiology, and hospital outcome. Am J Respir Crit Care Med 1998;157:1159-64 https://doi.org/10.1164/ajrccm.157.4.9704088
  2. Kallet RH, Jasmer RM, Pittet JF, Tang JF, Campbell AR, Dicker R, et al. Clinical implementation of the ARDS network protocol is associated with reduced hospital mortality compared with historical controls. Crit Care Med 2005;33: 925-9. https://doi.org/10.1097/01.CCM.0000162382.59289.9C
  3. MacCallum NS, Evans TW. Epidemiology of acute lung injury. Curr Opin Crit Care 2005;11:43-9 https://doi.org/10.1097/00075198-200502000-00007
  4. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ, et al. Bovine surfactant theraphy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997;155:1309-15 https://doi.org/10.1164/ajrccm.155.4.9105072
  5. Willson DF, Thomas NJ, Markovitz BP, Bauman LA, Dicarlo JV, Pon S, et al. Effect of exogenous surfactant (carfactant) in pediatric acute lung injury : a randomized controlled trial. JAMA 2005;293:470-6 https://doi.org/10.1001/jama.293.4.470
  6. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet 1967;2:319-23
  7. Ware LB, Matthay MA. The acute respiratory distress syndrome. New Engl J Med 2000;342:1334-49 https://doi.org/10.1056/NEJM200005043421806
  8. Bernard GR, Artigas KL, Carlet J, Falke K, Hudson L, Lamy M, et al. Report of the American-European Consensus conference on acute respiratory distress syndrome : definition, mechanism, relevant outcomes, and clinical trial coordination. Consensus Committee. J Crit Care 1994;9:72-81 https://doi.org/10.1016/0883-9441(94)90033-7
  9. The Acute Respiratory Distress Syndrome Network. Ventilation with low tidal volume as compared with traditional tidal volume. N Engl J Med 2000;342:1301-8 https://doi.org/10.1056/NEJM200005043421801
  10. Falke KJ, Pontoppidan H, Kumar A, Leith DE, Geffin B, Laver MB. Ventilation with end-expiratory pressure in acute lung disease. J Clin Invest 1972;51:2315-23 https://doi.org/10.1172/JCI107042
  11. Gattinoni L, Presenti A, Bombino M, Baglioni S, Rivolta M, Rossi F, et al. Relationships between lung computed tomographic density, gas exchange, and PEEP in acute respiratory failure. Anesthesiology 1988;69:824-32 https://doi.org/10.1097/00000542-198812000-00005
  12. Gunther A, Ruppert C, Schmidt R, Markart P, Grimminger F, Walmrath D, et al. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir Res 2001;2: 353-64 https://doi.org/10.1186/rr86
  13. Wright JR. Immunomodulatory functions of surfactant. Physiol Rev 1997;77:931-62 https://doi.org/10.1152/physrev.1997.77.4.931
  14. Herting E, Gan X, Rauprich P, Jarstrand C, Robertson B. Combined treatment with surfactant and specific immunoglobulin reduces bacterial proliferation in experimental neonatal group B strepsococcal pneumonia. Am J Resip Crit Care Med 1999;159:1862-7 https://doi.org/10.1164/ajrccm.159.6.9810047
  15. Anzueto A, Baughman R, Guntupalli KK, Weg JG, Wiedermann HP, Raventos AA, et al. Aerosolized surfactants in adults with sepsis induced acute respiratory distress syndrome. N Engl J Med 1996;334:1417-21 https://doi.org/10.1056/NEJM199605303342201
  16. Luce JM, Montgomery AB, Markers JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988;138:62-8 https://doi.org/10.1164/ajrccm/138.1.62
  17. Rothwell PM, Udwadia ZF, Lawler PG. Cortisol response to corticotropin and survival in septic shock. Lancet 1991;337: 582-3 https://doi.org/10.1016/0140-6736(91)91641-7
  18. Molijn GJ, Spek JJ, van Uffelen JC, de Jong FH, Brinkmann AO, Bruining HA, et al. Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. J Clin Endocrinol Metab 1995;80:1799-803 https://doi.org/10.1210/jc.80.6.1799
  19. Meduri GU, Tolley EA, Chinn A, Stentz F, Postlethwaite A. Procollagen types I and III aminoterminal propeptide levels during acute respiratory distress syndrome and in response to methylprednisolone treatment. Am J Respir Crit Care Med 1998;158:1432-41 https://doi.org/10.1164/ajrccm.158.5.9801107
  20. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelson T, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome : a randomized controlled trial. JAMA 1998;280:159-65 https://doi.org/10.1001/jama.280.2.159